Dexcom (Nadsaq:DXCM) announced today that it launched a new multi-region report evaluating type 2 diabetes treatments.

Dexcom has received a warning letter from the FDA, after the agency uncovered issues during two inspections of the continuous ...

Dexcom (Nadsaq:DXCM) today announced new insulin delivery integrations and updates on enhanced continuous glucose monitors ...

Medical device companies presented new data this week at the Advanced Technologies & Treatments for Diabetes conference.

At the conference, first-ever accuracy and performance data will be presented for Dexcom’s upcoming G7 15 Day system,1 ...

A survey conducted by the continuous glucose monitor maker Dexcom found that just over half of healthcare providers ranked technology and education as having larger impacts when it comes | Dexcom ...

DexCom, Inc. (NASDAQ: DXCM), a global leader in glucose biosensing ... first-ever accuracy and performance data for Dexcom G7 15 Day,1 will be presented, showcasing an overall mean absolute ...

Here are three highlights from the first day of the conference: 1. Dexcom previews new data for 15-day glucose monitor Dexcom shared the first data for its 15-day continuous glucose monitor ahead ...